Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Filings indexed 576 across all filing types
Latest filing 2021-08-10 Director's Dealing
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-06 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-06 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2021, for Tarsus Pharmaceuticals, Inc. It specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release with financial results for the three and six months ended June 30, 2021, is attached as Exhibit 99.1. The document itself is a current report providing an update on financial results, typical of an earnings release. The length is 3670 characters, which is relatively short and consistent with a Form 8-K earnings release filing. The document does not contain full financial statements or detailed analysis but references a press release with results. Therefore, this is best classified as an Earnings Release (ER).
2021-08-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.